The drugmaker said that as of Oct. 1, it will be responsible for distributing remdesivir in the U.S .and AmerisourceBergen will continue to serve as the sole U.S. distributor through the end of the year. AmerisourceBergen will sell remdesivir directly to hospitals.
Though the drug faced severe shortages in the spring and summer, it is no longer facing widespread shortages. Gilead released a statement Oct. 1 saying it is meeting real-time demand for remdesivir in the U.S. and anticipates meeting global demand in October, even in the event of a COVID-19 surge.
Gilead has taken more steps for full FDA approval of the drug, which it has named Veklury. It is on track to make more than $9 billion on the drug in 2020 and 2021, the Post reported, as a five-day treatment course is priced at $3,120. Gilead said it doesn’t plan to change the price.
Clinical studies have raised questions about the drug’s effectiveness, and the most conclusive studies have shown that it reduces hospital stays from 15 days to 11 but doesn’t significantly reduce the odds of dying from COVID-19, according to the Post.
Read the full article here.
More articles on pharmacy:
7 former FDA commissioners write opinion column lamenting White House’s treatment of agency
Celgene, Teva schemed to keep drug prices high, boost profits, US House panel finds
UnitedHealth acquires competitor to Amazon’s PillPack
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
